Kiadis banks $36M in a Euro IPO to fund its stem cell R&D

Damian Garde Dutch drug developer Kiadis Pharma pulled in €32.7 million ($ 36.3 million) in a European IPO, raising cash to develop a pair of stem cell treatments. FierceBiotech ...

UPDATED: Vertex wins a crucial FDA nod for its cystic fibrosis combo, prices at $259,000

Damian Garde Vertex Pharmaceuticals won the FDA's blessing to market a new combination therapy for cystic fibrosis, clearing the way for a drug key to the company's future as ...

Fast-growing Celgene snaps up Merck’s abandoned NJ campus

Tracy Staton Out with the old guard, in with the new. In another sign that Big Biotech is elbowing into the top levels of pharma, Celgene has agreed to buy Merck & Co.'s old ...

With vet drugs pumping, it’s no wonder that pharma’s eyeing M&A

Carly Helfand What's with all the M&A rumors floating around in the animal health world? Just look at Zoetis' Apoquel and it's clear why Big Pharma names are keen ...

HIV investigators at Harvard, J&J see promise in early-stage vaccine

John Carroll A team of collaborators drawn from Harvard, Johnson & Johnson and other groups published results from a preclinical animal study Thursday afternoon that underscores ...

Intercept files its ‘breakthrough’ liver drug for rare disease approval

Damian Garde Intercept Pharmaceuticals has submitted its top candidate to the FDA for approval in primary biliary cirrhosis, a rare disease that results in serious liver damage. FierceBiotech ...

Pharma to EU officials: We need ‘contingency’ supply plans in case of ‘Grexit’

Tracy Staton Drugmakers are raising an alarm about shortages in Greece as the possibility of a "Grexit" looms. That "worst-case scenario" could put supplies in peril, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS